Advertisement

Vitiligo pp 115-120 | Cite as

Koebner Phenomenon

  • Nanja van GeelEmail author
  • Reinhart Speeckaert
Chapter

Abstract

Koebner phenomenon (KP) is a well-known entity in dermatology. It was first described in 1876 by Heinrich Koebner, a German dermatologist, as “the development of lesions at sites of specifically traumatized uninvolved skin of patients with cutaneous diseases”. Since then, this isomorphic response has been reported in a several skin diseases, such as vitiligo, lichen planus, and psoriasis. In vitiligo a relation with disease activity has been suggested, as well as its possible negative influence on surgical treament results [1, 2].

References

  1. 1.
    Sagi L, Trau H. The Koebner phenomenon. Clin Dermatol. 2011;29:231–6.CrossRefGoogle Scholar
  2. 2.
    van Geel N, Speeckaert R, Taieb A, et al. Koebner’s phenomenon in vitiligo: European position paper. Pigment Cell Melanoma Res. 2011;24:564–73.CrossRefGoogle Scholar
  3. 3.
    Mazereeuw-Hautier J, Bezio S, Mahe E, et al. Segmental and non-segmental childhood vitiligo has distinct clinical characteristics: a prospective observational study. J Am Acad Dermatol. 2010;62:945–9.CrossRefGoogle Scholar
  4. 4.
    Barona MI, Arrunategui A, Falabella R, et al. An epidemiologic case-control study in a population with vitiligo. J Am Acad Dermatol. 1995;33:621–5.CrossRefGoogle Scholar
  5. 5.
    van Geel N, Speeckaert R, De Wolf S, et al. Clinical significance of Koebner phenomenon in vitiligo. Br J Dermatol. 2012;167:1017–24.CrossRefGoogle Scholar
  6. 6.
    Njoo MD, Das PK, Bos JD, et al. Association of the Koebner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol. 1999;135:407–13.PubMedGoogle Scholar
  7. 7.
    Sanjeev V, Mulekar MD, Marwan Asaad MD, et al. Koebner phenomenon in vitiligo: not always an indication of surgical failure. Arch Dermatol. 2007;143:799–816.Google Scholar
  8. 8.
    Ueki H. Koebner phenomenon in lupus erythematosus with special consideration of clinical findings. Autoimmun Rev. 2005;4:219–23.CrossRefGoogle Scholar
  9. 9.
    van Geel N, Speeckaert R, Mollet I, et al. In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial. Pigment Cell Melanoma Res. 2012;25(1):57–65.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of DermatologyGhent University HospitalGhentBelgium

Personalised recommendations